BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 52 resultados LastUpdate Última actualización 11/07/2020 [16:51:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   por página


IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS

NºPublicación: EP3675890A1 08/07/2020

Solicitante:

VITALITY WELLNESS NZ LTD [NZ]

CN_111278451_A

Resumen de: WO2019045575A1

Described herein are improvements relating to IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) biomarker for prediction of risk and recovery of non- neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing organic or plant based material such as concentrated extract of blackcurrant anthocyanins (BCA) for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 ratio along with a means to adjust cGP and cGP/IGF-1 ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data.

traducir

Biomarkers associated with Alzheimer's disease and applications thereof

NºPublicación: CN111363808A 03/07/2020

Solicitante:

聊城市第二人民医院

CN_110144397_A

Resumen de: CN110144397A

The invention discloses biomarkers associated with Alzheimer's disease and applications thereof, and relates to the applications of biomarkers, TES and PP1R18, in Alzheimer's disease, especially the application of TES or PPP1R18 in the diagnosis of Alzheimer's disease.

traducir

Molecular marker for developing Alzheimer diagnosis product

NºPublicación: CN111363809A 03/07/2020

Solicitante:

聊城市第二人民医院

CN_110144398_A

Resumen de: CN110144398A

The invention discloses a molecular marker for developing an Alzheimer diagnosis product. The molecular marker is EEF1AKMT3 and MANEAL. The invention particularly relates to an application of the molecular marker to preparation of an Alzheimer diagnosis product. Through in vitro detection of the EEF1AKMT3 and the MANEAL in samples, the molecular marker is applied.

traducir

SYSTEMS

NºPublicación: JP2020519286A 02/07/2020

Solicitante:

ニューヨークステムセルファウンデーションインコーポレイテッド

CN_111315871_A

Resumen de: WO2018206798A1

An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.

traducir

Brain Derived PPARa Ligands

NºPublicación: US2020206177A1 02/07/2020

Solicitante:

UNIV RUSH MEDICAL CENTER [US]

US_2019060269_A1

Resumen de: US2020206177A1

Methods of modulating peroxisome proliferator-activated receptor α (PPARα) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject where the PPARα ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT). Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject.

traducir

ANTIVIRAL AGENT FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE AND USE THEREOF

NºPublicación: WO2020138402A1 02/07/2020

Solicitante:

CLINIGEN K K [JP]

Resumen de: WO2020138402A1

The present invention provides a novel drug useful for fundamental therapy and prevention of Alzheimer's disease (AD). As a pharmaceutical composition for treating or preventing AD, a drug containing, as an active ingredient, a compound having anti-viral activity against HHV-6A, HHV-6B, and/or HHV-7, particularly foscarnet, is used. The drug does not only stop the progression of AD, but also is likely to serve as a fundamental therapeutic means. In addition, by using, as an AD biomarker, DNA or proteins of HHV-6A, HHV-6B, and/or HHV-7 derived from a subject's cerebrospinal fluid (CSF), blood plasma, blood, or saliva, or antibodies specific to HHV-6A, HHV-6B, and/or HHV-7 or fragments of the antibodies, the risk of developing AD or the state of progression of AD can be diagnosed, or the therapeutic effect of an antiviral agent used in the treatment of AD can be confirmed.

traducir

INHIBITOR OF TRPM-4 ION CHANNEL FOR TREATING OR PREVENTING NEURODEGENERATION

NºPublicación: US2020206167A1 02/07/2020

Solicitante:

UNIV HAMBURG EPPENDORF [DE]

US_2014378548_A1

Resumen de: US2020206167A1

The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.

traducir

METHOD FOR DETECTING THE PRESENCE AND QUANTITY OF THE LRP8 RECEPTOR AND OF ITS PROTEOLYTIC FRAGMENTS, DETECTION KIT AND RELATED ANTIBODIES

NºPublicación: WO2020136546A1 02/07/2020

Solicitante:

RUSSO CLAUDIO [IT]

Resumen de: WO2020136546A1

The present invention relates to a method for detecting by means of antibodies the presence and quantity of some substrates of γ-secretase and of fragments of said substrates, obtained both by the action of said γ-secretase or of other proteases, in biological samples isolated from the human body. The invention also relates to a kit for the detection of said substrates and fragments, as well as their antibodies to be used in the method and in the kit for the diagnosis of diseases such as Alzheimer's, Down syndrome and cancers. In particular, the antibodies are produced against specific C- terminal sequences of the protein LRP8 and its fragments.

traducir

BIOMARKERS AND METHODS FOR DETERMINING RISK FACTORS FOR ALZHEIMER'S DISEASE

NºPublicación: EP3674711A2 01/07/2020

Solicitante:

GRAVES STEVEN W [US]
KAUWE JOHN S K [US]

US_2017138964_A1

Resumen de: EP3674711A2

A method of determining risk factors for Alzheimer's disease in an individual, including assaying a biological medium obtained from the individual for a biomarker selected from Biomarker 1, Biomarker 2, Biomarker 3, or Biomarker 4, where Biomarker 1 has a mass-to-charge ratio (m/z) of 602.3, Biomarker 2 has a m/z of 804.6, Biomarker 3 has a m/z of 874.6, and Biomarker 4 has a m/z of 804.5, and where the presence of the two or more biomarkers in the individual indicates a risk factor of Alzheimer's disease.

traducir

DEVICE AND METHOD FOR DIAGNOSIS OF ALZHEIMER'S SYMPTOMS

NºPublicación: US2020199645A1 25/06/2020

Solicitante:

CONTROL OF INNATE IMMUNITY TECH RESEARCH ASSOCIATION [JP]
HAMAMATSU PHOTONICS KK [JP]
UNIV KAGAWA NAT UNIV CORP [JP]

CN_111094537_A

Resumen de: US2020199645A1

To provide a pathological index for Alzheimer's disease conveniently and with high precision, an Alzheimer's disease diagnosis device that includes a measurement means configured to measure one index or more selected from the group consisting of superoxide production activity, myeloperoxidase activity, oxidized LDL level, phagocytosis, triglycerides, fasting blood glucose, total cholesterol, hemoglobin A1c, and insulin in peripheral blood and a displaying means configured to display an index measured by the measurement means as a pathological index for Alzheimer's disease.

traducir

NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS

NºPublicación: US2020200768A1 25/06/2020

Solicitante:

MCBI INC [JP]

EP_3422007_A1

Resumen de: US2020200768A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.

traducir

ANTI-AMYLOID-BETA ANTIBODIES

NºPublicación: US2020199210A1 25/06/2020

Solicitante:

RPEPTIDE LLC [US]

US_2018051072_A1

Resumen de: US2020199210A1

The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (Aβ) protein. Such antibodies may be used for the modulation of Aβ activity and/or aggregation or amyloidosis, to study the effects of the Aβ protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with Aβ activity, aggregation, and/or amyloidosis.

traducir

BIOMARKER FOR COGNITIVE IMPAIRMENT DISORDERS AND DETECTION METHOD FOR COGNITIVE IMPAIRMENT DISORDERS USING SAID BIOMARKER

NºPublicación: US2020200767A1 25/06/2020

Solicitante:

UCHIDA KAZUHIKO [JP]
MCBI INC [JP]
UNIV TSUKUBA [JP]

EP_3654038_A1

Resumen de: US2020200767A1

This invention provides a method for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease using a protein and a peptide of the protein different in the presence level in subjects having a normal cognitive function and patients suffering from cognitive disfunction diseases and a biomarker for detecting cognitive disfunction diseases including mild cognitive impairment and Alzheimer's disease containing the protein and the peptide. This invention is a biomarker for diagnosing cognitive disfunction diseases containing a prothrombin precursor protein of SEQ ID NO: 1 or a peptide THRB containing the amino acid sequence represented by SEQ ID NO: 2 which is a peptide of the protein, a diagnosis method for cognitive disfunction diseases using the biomarker, an antigen peptide represented by SEQ ID NO: 3 for creating a THRB peptide specific antibody to be used in the diagnosis method, and a cognitive disfunction disease diagnosis kit containing the THRB peptide specific antibody.

traducir

ANTI-TAU ANTIBODIES AND METHODS OF USE

NºPublicación: CL2019003114A1 19/06/2020

Solicitante:

GENENTECH INC [US]
AC IMMUNE SA [CH]

US_2019367591_A1

Resumen de: WO2016196726A1

The invention provides anti-Tau antibodies and methods of using the same.

traducir

DENDRITIC CELL RECRUITMENT FROM BLOOD TO BRAIN IN NEURODEGENERATIVE DISEASE

NºPublicación: CN111315869A 19/06/2020

Solicitante:

精神免疫疗法公司

WO_2019094550_A1

Resumen de: WO2019094550A1

The present invention provides methods of treating neurodegenerative diseases, comprising administering agents that block dendritic cells from entering the brain from the blood. The present invention further describes methods for detecting the selective migration of dendritic cells from blood into brain as a marker of human neurodegenerative disease. The present invention further describes methods that can be used to evaluate and compare different embodiments of methods detecting migration of dendritic cells using transgenic mice that overexpress various mutations associated with induction of distinct neurodegenerative disease pathologies. These present inventions are particularly useful in the design and evaluation of clinical trials for neurodegenerative diseases, such as Alzheimer's disease, small vessel diseases that include cerebral amyloid angiopathy, and fronto-temporal dementias, and specifically for the design and evaluation of clinical trials of agents that block dendritic cells from entering the brain for therapeutic purpose.

traducir

SYSTEMS

NºPublicación: CN111315871A 19/06/2020

Solicitante:

纽约干细胞基金会有限公司

JP_2020519286_A

Resumen de: WO2018206798A1

An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.

traducir

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

NºPublicación: US2020190178A1 18/06/2020

Solicitante:

H LUNDBECK AS [DK]

US_2019177401_A1

Resumen de: US2020190178A1

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

traducir

CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS

NºPublicación: US2020190588A1 18/06/2020

Solicitante:

ST JOHNS UNIV [US]

WO_2018236589_A1

Resumen de: US2020190588A1

Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.

traducir

DIAGNOSING AND TREATING ALZHEIMER'S DISEASE

NºPublicación: US2020191804A1 18/06/2020

Solicitante:

UNIV BRIGHAM YOUNG [US]

WO_2018009727_A1

Resumen de: US2020191804A1

A method of treating a subject having Alzheimer's disease can include assaying a biological medium obtained from the subject for a biomarker selected from the group consisting of Biomarker 1, Biomarker 2, Biomarker 3, Biomarker 4, Biomarker 5, Biomarker 6, Biomarker 7, Biomarker 8, Biomarker 9, Biomarker 10, Biomarker 11, and combinations thereof, where Biomarker 1 has a mass-to-charge ratio (m/z) of 229.13, Biomarker 2 has a m/z of 514.38, Biomarker 3 has a m/z of 602.40, Biomarker 4 has a m/z of 620.42, Biomarker 5 has a m/z of 630.47, Biomarker 6 has a m/z of 703.56, Biomarker 7 has a m/z of 724.52, Biomarker 8 has a m/z of 778.54, Biomarker 9 has a m/z of 799.66, Biomarker 10 has a m/z of 824.60, and Biomarker 11 has a m/z of 842.66. The method can also include relating a characteristic of the biomarker to a presence of Alzheimer's disease in the subject and treating the subject for Alzheimer's disease.

traducir

Methods for evaluating and improving cognitive function

NºPublicación: AU2018363883A1 18/06/2020

Solicitante:

THE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH [AU]
UNIV MELBOURNE [AU]

WO_2019090393_PA

Resumen de: AU2018363883A1

The present invention generally relates to method for evaluating and improving cognitive function in a subject. In particular, the invention generally relates to methods for evaluating cognitive function in a subject by determining the level of cholesteryl esters in a subject, and to improving cognitive function in a subject comprising the administration of cholesteryl oleate, or analogues thereof.

traducir

NEURON-DERIVED EXOSOMES AND THEIR BIOMARKERS FOR THE DIAGNOSIS, PROGNOSIS, AND TREATMENT OF TRAUMATIC BRAIN INJURY AND ALZHEIMER'S DISEASE

NºPublicación: WO2020123884A1 18/06/2020

Solicitante:

GOETZL EDWARD J [US]

Resumen de: WO2020123884A1

The present invention relates to plasma neuron-derived exosomal protein biomarkers and diagnostic and prognostic methods for traum atic brain injury (TBI) and neuropathogenicafly related neurodegenerative diseases, such as AD. The invention also provides compositions for detecting neuron-derived exosomes and neuron-derived exosomal protein biomarkers as well as compositions and methods useful for treating acute TBI, chronic repetitive TBI by preventing progression to chronic traumatic encephalopathy (CTE), and Alzheimer' s disease (AD).

traducir

IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS

NºPublicación: CN111278451A 12/06/2020

Solicitante:

维泰利特健康(新西兰)有限公司

AU_2018323787_A1

Resumen de: WO2019045575A1

Described herein are improvements relating to IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) biomarker for prediction of risk and recovery of non- neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing organic or plant based material such as concentrated extract of blackcurrant anthocyanins (BCA) for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 ratio along with a means to adjust cGP and cGP/IGF-1 ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data.

traducir

SCREENING METHOD

NºPublicación: US2020182850A1 11/06/2020

Solicitante:

TAKEDA PHARMACEUTICALS CO [JP]

JP_WO2018212312_A1

Resumen de: US2020182850A1

The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.

traducir

METHODS OF DIAGNOSING A DISEASE STATE

NºPublicación: WO2020113271A1 11/06/2020

Solicitante:

LA TROBE UNIV [AU]

Resumen de: WO2020113271A1

The present invention relates to microRNA biomarkers for the diagnosis, monitoring and therapy of neurodegenerative disorders including Parkinson's Disease, Alzheimer's Disease and prion diseases.

traducir

METHODS OF DETECTING, PREVENTING, REVERSING, AND TREATING NEUROLOGICAL DISEASES

Nº publicación: WO2020118056A1 11/06/2020

Solicitante:

UNIV WASHINGTON [US]

Resumen de: WO2020118056A1

Among the various aspects of the present disclosure is the provision of a method of detecting, preventing, reversing, treating, or delaying the onset of a neurological disease (e.g., adult-onset neurological diseases, Alzheimers disease, Parkinsons disease, Frontotemporal dementia).

traducir

Página1 de 3 nextPage por página

punteroimgVolver